-

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Announces Investigation into NovoCure Limited (NVCR)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, is investigating whether NovoCure Limited (“NovoCure” or the “Company”) (NYSE: NVCR) and certain of its officers and directors issued false and/or misleading statements and/or failed to disclose information pertinent to investors in violation of federal securities laws. If you purchased or otherwise own NovoCure securities, and have suffered a loss, you are encouraged to contact Jonathan Zimmerman at (888) 398-9312 for more information.

CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION

NovoCure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its Tumor Treating Fields ("TTFields") therapy.

On June 6, 2023, NovoCure issued a press release announcing "positive results" from the Phase 3 LUNAR clinical trial evaluating the use of its TTFields therapy together with standard therapies for the treatment of non-small cell lung cancer. Despite reporting an observable difference in median overall survival between patients receiving TTFields, combined with standard therapies compared patients treated only with standard therapies, analysts expressed concerns about the test population and the commercial prospects of the device.

On this news, NovoCure's stock fell from $82.51 per share to $47 per share, representing a decline of over 43%.

What You Can Do – CLICK HERE

If you purchased or otherwise own NovoCure securities and have suffered a loss, realized or unrealized, and you wish to discuss this investigation, please contact attorney Jonathan Zimmerman at (888) 398-9312, or at jzimmerman@scott-scott.com.

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

Attorney Advertising

Contacts

Scott+Scott Attorneys at Law LLP

NYSE:NVCR

Release Versions

Contacts

More News From Scott+Scott Attorneys at Law LLP

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Cardinal Infrastructure Group Inc. (NASDAQ: CDNL)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, alerts investors that it is investigating potential violations of U.S. federal securities laws involving Cardinal Infrastructure Group Inc. (NASDAQ: CDNL).CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTIONWhat is Cardinal Infrastructure?Cardinal Infrastructure is a North Carolina-based infrastructure construction company specializing in under...

SIX FLAGS ENTERTAINMENT CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Six Flags Entertainment Corporation’s Directors and Officers for Breach of Fiduciary Duties – FUN

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Six Flags Entertainment Corporation (NYSE: FUN) failed to manage Six Flags in an acceptable manner, breaching their fiduciary duties to Six Flags, and whether Six Flags and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know:On October 12, 2026, a man died after bein...

BOSTON SCIENTIFIC CORPORATION INVESTOR ALERT:  Scott+Scott Attorneys at Law LLP Investigates Boston Scientific Corporation’s Directors and Officers for Breach of Fiduciary Duties – BSX

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Boston Scientific Corporation (NYSE: BSX) failed to manage Boston Scientific in an acceptable manner, breaching their fiduciary duties to Boston Scientific, and whether Boston Scientific and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On February 4, 2026, B...
Back to Newsroom